β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

INTRODUCTION: The overexpression of human epidermal growth factor receptor (HER)-2 in 20% of human breast cancers and its association with aggressive growth has led to widespread use of HER2-targeted therapies, such as trastuzumab (T) and lapatinib (L). Despite the success of these drugs, their effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Catherine, Park, Catherine C, Hilsenbeck, Susan G, Ward, Robin, Rimawi, Mothaffar F, Wang, Yen-chao, Shou, Jiang, Bissell, Mina J, Osborne, C Kent, Schiff, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236347/
https://www.ncbi.nlm.nih.gov/pubmed/21884573
http://dx.doi.org/10.1186/bcr2936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236347/
https://www.ncbi.nlm.nih.gov/pubmed/21884573
http://dx.doi.org/10.1186/bcr2936

Ejemplares similares